CRH is not a biotech stockCRH is a straightforward busines with tangible give and take and without hype, a feature prevalent with all biotech stocks. It provides services and does not market pharmaceutical products subject to price gouging and price controls. That is why the political rhetoric in Washington has little or no effect on the price of the stock. And in due time, this stock will be "the go to" health care stock despite other options that might be available to patients. In my opinion, due to the fragmentation of the anesthesia health sector, there is plenty of room for growth and amagalmation of the industry. The next two years will be critical for the company to consolidate and increase capitalization over half a billion. So steady as she goes, the stock will move up in line with earning and ROE and not on hype. Biotech stocks were trashed because, valuations were based on future Return On Equity and not current and CRH here makes the difference.